160 related articles for article (PubMed ID: 31004381)
41. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
42. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
43. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
[TBL] [Abstract][Full Text] [Related]
44. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Siegel DS; Weisel KC; Dimopoulos MA; Baz R; Richardson P; Delforge M; Song KW; San Miguel JF; Moreau P; Goldschmidt H; Cavo M; Jagannath S; Yu X; Hong K; Sternas L; Zaki M; Palumbo A
Leuk Lymphoma; 2016 Dec; 57(12):2833-2838. PubMed ID: 27267105
[TBL] [Abstract][Full Text] [Related]
45. Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.
Khan R; Apewokin S; Grazziutti M; Yaccoby S; Epstein J; van Rhee F; Rosenthal A; Waheed S; Usmani S; Atrash S; Kumar S; Hoering A; Crowley J; Shaughnessy JD; Barlogie B
Leukemia; 2015 May; 29(5):1195-201. PubMed ID: 25640885
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
Bridoux F; Chen N; Moreau S; Arnulf B; Moumas E; Abraham J; Desport E; Jaccard A; Fermand JP
Cancer Chemother Pharmacol; 2016 Jul; 78(1):173-82. PubMed ID: 27286995
[TBL] [Abstract][Full Text] [Related]
47. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
[TBL] [Abstract][Full Text] [Related]
48. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
Kasamatsu T; Saitoh T; Ino R; Gotoh N; Mitsui T; Shimizu H; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Murakami H
Hematol Oncol; 2017 Dec; 35(4):711-718. PubMed ID: 27405747
[TBL] [Abstract][Full Text] [Related]
49. [Clinical analysis of newly diagnosed multiple myeloma patients with renal dysfunction].
Zhu W; Lu J; Lu J; Hou J; Huang X; Chen W
Zhonghua Yi Xue Za Zhi; 2015 Mar; 95(10):741-4. PubMed ID: 26080844
[TBL] [Abstract][Full Text] [Related]
50. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy.
Kurihara K; Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Hatta Y; Nakayama T; Takei M
Med Oncol; 2019 Jul; 36(9):75. PubMed ID: 31342211
[TBL] [Abstract][Full Text] [Related]
51. Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment.
Dimopoulos MA; Terpos E; Goldschmidt H; Alegre A; Mark T; Niesvizky R
Cancer Treat Rev; 2012 Dec; 38(8):1012-9. PubMed ID: 22609463
[TBL] [Abstract][Full Text] [Related]
52. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].
Wu Q; Liu JR; Huang BH; Zou WY; Gu JL; Chen ML; Kuang LF; Zheng D; Xu DR; Zhou ZH; Wang HH; Su C; Tong XZ; Li J
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):453-459. PubMed ID: 31340616
[No Abstract] [Full Text] [Related]
53. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
54. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.
Roussou M; Kastritis E; Migkou M; Psimenou E; Grapsa I; Matsouka C; Barmparousi D; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2008 May; 49(5):890-5. PubMed ID: 18464107
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
San-Miguel JF; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Neuwirth R; Boral AL; Esseltine DL; Anderson KC
Leukemia; 2008 Apr; 22(4):842-9. PubMed ID: 18200040
[TBL] [Abstract][Full Text] [Related]
56. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.
Antlanger M; Dust T; Reiter T; Böhm A; Lamm WW; Gornicec M; Willenbacher E; Nachbaur D; Weger R; Rabitsch W; Rasoul-Rockenschaub S; Worel N; Lechner D; Greinix H; Keil F; Gisslinger H; Agis H; Krauth MT
BMC Cancer; 2018 Oct; 18(1):1008. PubMed ID: 30342509
[TBL] [Abstract][Full Text] [Related]
57. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
58. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
59. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
60. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
Dimopoulos MA; Merlini G; Bridoux F; Leung N; Mikhael J; Harrison SJ; Kastritis E; Garderet L; Gozzetti A; van de Donk NWCJ; Weisel KC; Badros AZ; Beksac M; Hillengass J; Mohty M; Ho PJ; Ntanasis-Stathopoulos I; Mateos MV; Richardson P; Blade J; Moreau P; San-Miguel J; Munshi N; Rajkumar SV; Durie BGM; Ludwig H; Terpos E;
Lancet Oncol; 2023 Jul; 24(7):e293-e311. PubMed ID: 37414019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
